Article Text

Download PDFPDF

  1. Palmer Netongo1,
  2. Séverin Kamdem1,
  3. Thirumalaisamy Velavan2,
  4. Peter Kremsner2
  1. 1University of Yaoundé I, Cameroon
  2. 2ITM Tübingen, Germany


Background As the decline in malaria cases becomes obvious in most sub-Saharan African countries, a new major concern is accurate diagnosis of low parasitaemia which can cause sub-patent infections and false-negative Rapid Diagnostic Test (RDT) results. We assessed the accuracy malaria diagnosis by RDT and microscopy are currently been conducted in Cameroon, by re-evaluating some samples from patients who sought medical care at three health centres in Yaounde. The study would provide information which can help the national malaria control program to reorient interventions strategies to enhance accurate diagnosis within the country.

Methods We undertook a research project within a period of six months to re-evaluate malaria confirmed cases by microscopy and RDT test (HRP2: SD BIOLINE Malaria Ag P.f/Pan: Optimal screening test for P. falciparum and other Plasmodium species). We used molecular methods such as nested PCR, in-house tailored loop amplified isothermal amplification (LAMP) and GenoType MalariaDR molecular assay to revalidate these samples. DNA was directly extracted from the RDT cassettes using qiagen spin columns.

Results Results showed discrepancies in malaria diagnosis by microscopy, RDT, PCR, LAMP and GenoType MalariaDR. Most false negatives results (RDT negative but positive by microscopy and molecular methods) are linked to low parasite density usually<150 asexual parasites/μl. However, there were some cases where higher parasite density >5,00/μl could lead to false negative results (linked to a deletion of about 870 bp in the HRP-2 gene). GenoType MalariaDR revealed the presence of mutations on Pfmdr1 and Pfcrt associated with resistance to ART.

Conclusions The study provided factual information on the detected P. falciparum isolates, HRP-2 mutations and the performance of RDTs and Pfmdr1, Pfcrt and ART resistance markers present in the population. The first-line of ACT in Cameroon is artesunate+amodiaquine, yet possible resistance isolates of amodiaquine and artesunate could be circulating in the country.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.